Azacitidine (AZA) prolongs overall survival in older patients with acute myeloid leukemia (AML) with poor prognostic karyotypes compared with conventional care regimens (CCR)

Bibliographic Details
Main Authors:	Doehner, H, Vyas, P, Seymour, JF, Santini, V, Stone, RM, Minden, MD, Al-Ali, HK, Del Castillo, TB, Morrill, J, Songer, S, Weaver, J, Skikne, BS, Beach, CL, Dombret, H
Format:	Conference item
Published:	American Society of Hematology 2016

Similar Items